Sheahan K - Search Results

1

Controversies in the pathological assessment of colorectal cancer.

Maguire A, Sheahan K. Maguire A, et al. Among authors: sheahan k. World J Gastroenterol. 2014 Aug 7;20(29):9850-61. doi: 10.3748/wjg.v20.i29.9850. World J Gastroenterol. 2014. PMID: 25110416 Free PMC article. Review.

2

Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.

Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, Sheahan K. Mulcahy HE, et al. Among authors: sheahan k. Lancet. 1994 Aug 27;344(8922):583-4. doi: 10.1016/s0140-6736(94)91968-2. Lancet. 1994. PMID: 7914963

3

Pathological evidence in support of total mesorectal excision in the management of rectal cancer.

Reynolds JV, Joyce WP, Dolan J, Sheahan K, Hyland JM. Reynolds JV, et al. Among authors: sheahan k. Br J Surg. 1996 Aug;83(8):1112-5. doi: 10.1002/bjs.1800830826. Br J Surg. 1996. PMID: 8869320

4

Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.

Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell TG, O'Donoghue DP, Sheahan K. Skelly MM, et al. Among authors: sheahan k. Clin Cancer Res. 1997 Oct;3(10):1837-40. Clin Cancer Res. 1997. PMID: 9815571

5

The relationship between cyclooxygenase-2 expression and colorectal cancer.

Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, Murray FE. Sheehan KM, et al. Among authors: sheahan k. JAMA. 1999 Oct 6;282(13):1254-7. doi: 10.1001/jama.282.13.1254. JAMA. 1999. PMID: 10517428

6

Peritoneal involvement in stage II colon cancer.

Lennon AM, Mulcahy HE, Hyland JM, Lowry C, White A, Fennelly D, Murphy JJ, O'Donoghue DP, Sheahan K. Lennon AM, et al. Among authors: sheahan k. Am J Clin Pathol. 2003 Jan;119(1):108-13. doi: 10.1309/J6BD-TWM2-M792-TN2V. Am J Clin Pathol. 2003. PMID: 12520705

7

Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer.

Sheehan KM, O'Donovan DG, Fitzmaurice G, O'Grady A, O'Donoghue DP, Sheahan K, Byrne MF, Conroy RM, Kay EW, Murray FE. Sheehan KM, et al. Among authors: sheahan k. Eur J Gastroenterol Hepatol. 2003 Apr;15(4):375-80. doi: 10.1097/00042737-200304000-00007. Eur J Gastroenterol Hepatol. 2003. PMID: 12655257

8

Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression.

Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP. Troy AM, et al. Among authors: sheahan k. Eur J Cancer. 2004 Jul;40(10):1610-6. doi: 10.1016/j.ejca.2004.03.011. Eur J Cancer. 2004. PMID: 15196548

9

Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D, Sheahan K. Ryan R, et al. Among authors: sheahan k. Histopathology. 2005 Aug;47(2):141-6. doi: 10.1111/j.1365-2559.2005.02176.x. Histopathology. 2005. PMID: 16045774

10

Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.

Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D, Sheahan K. Wang LM, et al. Among authors: sheahan k. Am J Surg Pathol. 2009 Jan;33(1):134-41. doi: 10.1097/PAS.0b013e318184cd55. Am J Surg Pathol. 2009. PMID: 18971777

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

250 results

Search Page

Filters